Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Emily Field
BARC
Emily Field
Barclays
Wall Street Analyst
★★★☆☆
#837
on 13Foresight · ranked by our own returns
54%
Success Rate
+0.0%
Average Return
13 of 24 calls profitable · -2.5% vs benchmark
📈 Across the calls we could measure, roughly 54% of Emily Field's ratings turned a profit when each position was held for 1 year — averaging +0.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 27 Hold 10 Sell
Emily's Stock Coverage 33 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
LLY
Eli Lilly & Co
 Jun 15, 2026 BUY Strong Buy
-10.5% avg upside
47 analysts
$1400.00
27.34% Upside
 -2.7%
PFE
Pfizer
 Jun 15, 2026 SELL Buy
+34.2% avg upside
45 analysts
$25.00
0.81% Downside
 +3.0%
ABBV
AbbVie
 Jun 12, 2026 BUY Buy
+2.9% avg upside
43 analysts
$275.00
27.08% Upside
 -2.9%
BMY
Bristol-Myers Squibb
 Jun 02, 2026 BUY Buy
+9.1% avg upside
42 analysts
$75.00
38.95% Upside
 +1.5%
MRK
Merck & Company
 Jun 01, 2026 BUY Strong Buy
+10.7% avg upside
43 analysts
$140.00
23.02% Upside
 +1.0%
BIIB
Biogen
 May 14, 2026 HOLD Strong Buy
+25.1% avg upside
51 analysts
$185.00
5.92% Downside
 +3.8%
AMGN
Amgen
 May 05, 2026 HOLD Buy
-11.6% avg upside
57 analysts
$350.00
3.62% Upside
 +3.2%
GILD
Gilead Sciences
 Apr 21, 2026 HOLD Strong Buy
-4.8% avg upside
66 analysts
$155.00
25.30% Upside
 -6.5%
CYTK
Cytokinetics
 Apr 06, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$95.00
20.61% Upside
 +21.6%
GSK
GlaxoSmithKline
 Jan 06, 2026 SELL Hold
-13.9% avg upside
19 analysts
 — -5.8%
RHHBY
Roche Holding
 Jan 06, 2026 BUY Buy
+0.3% avg upside
14 analysts
 — +2.8%
SNY
Sanofi
 Jan 06, 2026 HOLD Strong Buy
+74.4% avg upside
20 analysts
 — -3.0%
NVS
Novartis
 Jan 06, 2026 HOLD Hold
-7.5% avg upside
24 analysts
 — +9.3%
CH:ROP
Roche Holding AG
 Sep 24, 2025 HOLD Buy
+3.3% avg upside
23 analysts
$275.00
13.96% Downside
 ·
FR:SAN
Sanofi
 Aug 12, 2025 BUY Strong Buy
+32.9% avg upside
30 analysts
$105.00
41.54% Upside
 ·
GB:GSK
GlaxoSmithKline
 Aug 12, 2025 HOLD Hold
-2.9% avg upside
25 analysts
$1450.00
24.63% Downside
 ·
CH:SDZ
Sandoz Group Ltd
 Aug 08, 2025 BUY Buy
-7.8% avg upside
10 analysts
$55.00
19.07% Downside
 ·
GB:0QIU
Novo Nordisk
 Aug 04, 2025 HOLD Hold
+43.2% avg upside
28 analysts
$375.00
27.90% Upside
 ·
GB:AZN
AstraZeneca
 Jul 30, 2025 BUY Strong Buy
+12.2% avg upside
26 analysts
$14000.00
5.84% Upside
 ·
NL:LKFT
Galapagos
 Jul 29, 2025 SELL Sell
+112.9% avg upside
16 analysts
$22.00
10.59% Downside
 ·
CH:NOVN
Novartis AG
 Jul 21, 2025 SELL Buy
-9.8% avg upside
30 analysts
$90.00
23.98% Downside
 ·
DE:BAYN
Bayer
 Jun 27, 2025 HOLD Strong Buy
+33.6% avg upside
28 analysts
$25.00
33.91% Downside
 ·
GB:HIK
Hikma Pharmaceuticals
 Apr 25, 2025 HOLD Buy
+64.1% avg upside
7 analysts
$2000.00
37.28% Upside
 ·
GB:0MGB
Genmab A/S
 Apr 15, 2025 BUY Buy
+31.5% avg upside
22 analysts
$2100.00
27.92% Upside
 ·
DE:MRK
Merck KGaA
 Oct 29, 2024 BUY Buy
+2.2% avg upside
32 analysts
$195.00
46.74% Upside
 ·
GB:0QW0
arGEN X
 Jun 21, 2023 BUY Strong Buy
-24.9% avg upside
24 analysts
$430.00
44.00% Downside
 ·
ES:GRF
Grifols
 Nov 21, 2022 SELL Buy
+64.4% avg upside
12 analysts
$9.00
1.14% Downside
 ·
FR:IPN
Ipsen
 Nov 25, 2021 SELL Buy
-21.9% avg upside
17 analysts
$75.00
52.14% Downside
 ·
GB:0NZT
UCB SA
 Oct 15, 2021 HOLD Buy
-15.2% avg upside
19 analysts
$90.00
63.92% Downside
 ·
LKFT
Lakefront Biotherapeutics
 Jan 19, 2021 HOLD Hold
+272.6% avg upside
24 analysts
$125.00
341.76% Upside
 ·
HK:0013
HUTCHMED (China)
Aug 28, 2020 HOLD Buy
+619.1% avg upside
6 analysts
$51.85
215.74% Upside
 ·
RVLPQ
RVL Pharmaceuticals
 Apr 25, 2019 BUY Strong Buy
+624999900.0% avg upside
6 analysts
$14.00
1399999900.07% Upside
 -6.8%
GRFS
Grifols SA
 Jun 01, 2018 BUY Buy
+247.6% avg upside
12 analysts
$33.29
349.76% Upside
 -19.0%
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Emily Field — Frequently Asked Questions
How accurate are Emily Field's stock ratings?
Based on the calls 13Foresight could measure, about 54% of Emily's ratings were profitable over a one-year hold, with an average return of +0.0% per rating, or -2.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Emily ranked on 13Foresight?
Emily Field is currently ranked #837 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Emily cover?
Emily most recently has ratings on LLY, PFE, ABBV, BMY, MRK, BIIB, AMGN, GILD, CYTK, GSK, RHHBY, SNY and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.